Walvax Biotechnology
Chinese vaccine company listed on the Shenzhen Stock Exchange ChiNext under the name Walvax Biotechnology and ticker 300142.
Last updated October 12, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Walvax Biotechnology is a vaccine company that was registered and established in 2001. It listed on the Shenzhen Stock Exchange ChiNext in 2010 under the securities name "沃森生物" and code "300142". Its marketed products include the 13-valent pneumococcal polysaccharide conjugate vaccine, the 23-valent pneumococcal polysaccharide vaccine, the Haemophilus influenzae type b conjugate vaccine, the group A and C meningococcal polysaccharide conjugate vaccine, the ACYW135 meningococcal polysaccharide vaccine, the bivalent human papillomavirus vaccine (Pichia pastoris), the group A and C meningococcal polysaccharide vaccine, and the adsorbed acellular DTP combined vaccine.
History
Walvax Biotechnology was registered and established in 2001. In 2002 it received 2 million yuan in funding from the Ministry of Science and Technology's "863" Program. In 2004 it began planning and construction of the "Yuxi Vaccine Production Base" and received 20 million yuan from technology transfer. In 2007 its first product, the Haemophilus influenzae type b conjugate vaccine, was launched, and phase two construction of the Yuxi vaccine production base began. In 2009 the group A and C meningococcal polysaccharide conjugate vaccine went into production and was launched for sale. In 2010 the company was listed on the Shenzhen Stock Exchange ChiNext, with the securities name "沃森生物" and securities code "300142". In 2011 it set out a ten-year strategic development plan with three major strategies: import substitution, made in China, and internationalization, and was recognized as a national enterprise technology center. In 2012 the group A and C meningococcal polysaccharide vaccine and the ACYW135 meningococcal polysaccharide vaccine were launched, and the Haemophilus influenzae type b conjugate vaccine was formally exported to the Philippines, marking Walvax's first step toward internationalization. In 2015 the first employee stock ownership plan was implemented, and Shanghai Zerun signed an agreement with the Gates Foundation on "low-cost HPV vaccine development and WHO prequalification," receiving US$5 million in project funding to accelerate the development and industrialization of an HPV (types 16/18) vaccine (yeast). In 2017 the company's adsorbed acellular DTP combined vaccine was launched, the 23-valent pneumococcal polysaccharide vaccine was launched, and the ACYW135 meningococcal polysaccharide vaccine received a halal certificate from the Indonesian Ulema Council. In 2019 it set a new ten-year development strategy clarifying three major strategies: comprehensive internationalization, Industry 4.0, and import substitution, and the 13-valent pneumococcal polysaccharide conjugate vaccine was approved. In 2020 the 13-valent pneumococcal polysaccharide conjugate vaccine was launched for sale, the bivalent HPV vaccine received a new drug production application acceptance notice from the National Medical Products Administration, a novel coronavirus mRNA vaccine jointly developed with the Academy of Military Medical Sciences and Abogen Biosciences entered phase I clinical trials, and a chimpanzee adenovirus vector COVID-19 vaccine jointly developed with Tsinghua University and Tianjin Medical University was about to file for clinical trials. In 2021 the novel coronavirus mRNA vaccine jointly developed with the Academy of Military Medical Sciences and Abogen Biosciences began overseas phase III clinical trials, and a modular mRNA COVID-19 vaccine plant was put into use with an expected capacity of 200 million doses per year. In 2022 the 13-valent pneumococcal polysaccharide conjugate vaccine was successfully exported to Morocco, the bivalent HPV vaccine was approved for marketing, and the company advanced multiple strategic R&D projects, achieving milestone results particularly in its mRNA R&D technology platform.
- 2022
13-valent pneumococcal conjugate vaccine exported to Morocco; bivalent HPV vaccine approved for marketing.
- 2021
mRNA COVID-19 vaccine began overseas Phase III trials; modular mRNA vaccine manufacturing facility put into use with expected annual capacity of 200 million doses.
- 2020
13-valent pneumococcal conjugate vaccine launched; bivalent HPV vaccine received new drug production application acceptance; mRNA COVID-19 vaccine entered Phase I; chimpanzee adenovirus-vectored COVID-19 vaccine about to file for clinical trials.
- 2019
New ten-year strategy set: comprehensive internationalization, Industry 4.0, import substitution; 13-valent pneumococcal polysaccharide conjugate vaccine approved.
- 2017
DTaP vaccine and 23-valent pneumococcal polysaccharide vaccine launched; ACYW135 meningococcal polysaccharide vaccine received halal certificate from Indonesian Ulema Council.
- 2015
First employee stock ownership plan implemented; Shanghai Zerun signed agreement with Gates Foundation for low-cost HPV vaccine development and WHO prequalification, receiving $5 million grant.
- 2012
Group A and C meningococcal polysaccharide vaccine and ACYW135 meningococcal polysaccharide vaccine launched; Hib vaccine exported to the Philippines.
- 2011
Defined ten-year strategic plan: import substitution, Chinese manufacturing, internationalization; recognized as National Enterprise Technology Center.
- 2010
Listed on Shenzhen Stock Exchange ChiNext board under ticker 300142.
- 2009
Group A and C meningococcal polysaccharide conjugate vaccine launched.
Products and positioning
13-valent pneumococcal polysaccharide conjugate vaccine
Launched in December 2019; for infants from 2 months of age (minimum 6 weeks) to children under 5 years (before their 6th birthday); prevents pneumococcal disease caused by 13 serotypes.
23-valent pneumococcal polysaccharide vaccine
Launched in 2017; for high-risk groups among children over 2 years of age and adults; prevents pneumococcal disease caused by 23 serotypes.
Haemophilus influenzae type b conjugate vaccine
Launched in 2007; for infants from 2 months of age to children under 5 years; prevents diseases caused by Haemophilus influenzae type b.
Group A and C meningococcal polysaccharide conjugate vaccine
Launched in 2009; for infants from 3 months of age to children under 5 years; prevents diseases caused by group A or C meningococcus.
ACYW135 meningococcal polysaccharide vaccine
Launched in 2012; for high-risk groups among children over 2 years of age and adults; prevents diseases caused by the corresponding bacterial groups.
Bivalent human papillomavirus vaccine (Pichia pastoris)
Officially launched in 2022; for females aged 9-30; mainly prevents diseases caused by high-risk HPV types 16 and 18, such as cervical cancer, grade 2 and 3 cervical intraepithelial neoplasia (CIN2/3), and cervical adenocarcinoma in situ (AIS).
Group A and C meningococcal polysaccharide vaccine
Launched in 2012; for children over 2 years of age and adults; prevents epidemic cerebrospinal meningitis caused by group A and C meningococcus.
Adsorbed acellular DTP combined vaccine
Launched in 2015; a national immunization program vaccine; for children aged 3 months to 5 years; prevents pertussis, diphtheria, and tetanus.
Controversies
Recent events
Nearshore Protein and Yuxi Watson sign mRNA vaccine materials agreement[8]
Reported:
Nearshore Protein and Yuxi Watson signed a strategic agreement for the supply of raw-material enzymes for Watson Bio's mRNA vaccine project.
Watson Biotech announces plan to acquire a 13.04% stake in Shanghai Zerun[9]
Reported:
Watson Biotech announced an agreement to acquire a 13.04% stake in Shanghai Zerun, subject to the agreement's conditions precedent. The announced transaction could involve acquiring the stake from two investment partnerships or acquiring their partnership interests.
Walvax Biotechnology wins two awards at the 2019 China Listed Companies Reputation List[10]
Walvax Biotechnology won the Most Growth-Oriented Listed Company in the Healthcare Industry award and the Best Listed Company Secretary award at the 2019 China Listed Companies Reputation List.
Sources10 sources
Cite this profile: Cite the canonical profile. /brand-wiki/沃森生物 · Editorial policy · How profiles are compiled